{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:03:51Z","timestamp":1792631031697,"version":"4.5.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcitonin gene-related peptide has shown to play a central role in cluster headache (CH) pathophysiology. A clinical trial with galcanezumab was carried out in chronic cluster headache (CCH) but did not meet its primay endpoint. However, its off-label use in patients with CCH refractory to other therapies could be considered. We aimed to asses the efficacy and safety of galcanezumab as CCH preventive treatment in a real-life setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational study was conducted. Patients with CCH who received at least one dose of 240\u2009mg of galcanezumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one patients who tried a mean of 6.3\u2009\u00b1\u20091.9 preventive therapies, including onabotulinumtoxinA in 90.5%. At baseline, the median of frequency was 60 (37.5\u2013105) monthly attacks with 10 (8.3\u201310) points in pain intensity (Numerical Rating Scale). After one month, the frequency decreased to 31 (10.5\u201345) ( p\u2009=\u20090.003) with 8.5 (8\u20139.5) intensity ( p\u2009=\u20090.007); 10 (47.6%) patients were 50% responders of whom four (19%) were 75% responders. Of the 15 patients with 3 months of follow-up, seven (46.6%) reduced their frequency by 50% and four (26.6%) by 75%, with 40 (10\u201360) monthly attacks ( p\u2009=\u20090.07) and pain intensity of 8 (5\u201310) ( p\u2009=\u20090.026). Some 52% patients experienced adverse events, mostly mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our cohort of refractory CCH, galcanezumab was effective in almost 50% of patients. This finding supports individual off-label treatment attempts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024231226181","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:05:47Z","timestamp":1710839147000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study"],"prefix":"10.1177","volume":"44","author":[{"given":"Raquel","family":"Lamas P\u00e9rez","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mill\u00e1n-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Oria","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"bibr1-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr2-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01592.x"},{"key":"bibr3-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00735-5"},{"key":"bibr4-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1991.1104169.x"},{"key":"bibr5-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/head.13711"},{"key":"bibr6-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01566.x"},{"key":"bibr7-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2017.09.003"},{"key":"bibr8-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413493193"},{"key":"bibr9-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419839992"},{"key":"bibr10-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-79"},{"key":"bibr11-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12129"},{"key":"bibr12-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.05.016"},{"key":"bibr13-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-12-112"},{"key":"bibr14-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.15.5731"},{"key":"bibr15-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230214"},{"key":"bibr16-03331024231226181","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10010030"},{"key":"bibr17-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.2.283"},{"key":"bibr18-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.3.427"},{"key":"bibr19-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1675"},{"key":"bibr20-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813440"},{"key":"bibr21-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905321"},{"key":"bibr22-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420949866"},{"key":"bibr23-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/head.14404"},{"key":"bibr24-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05624-1"},{"key":"bibr25-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/head.14234"},{"key":"bibr26-03331024231226181","doi-asserted-by":"publisher","DOI":"10.1111\/head.14292"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231226181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024231226181","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231226181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:14Z","timestamp":1777387574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024231226181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1177\/03331024231226181"],"URL":"https:\/\/doi.org\/10.1177\/03331024231226181","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"article-number":"03331024231226181"}}